Unlocking the Potential of Biomarkers in Varied CardiovascularAssociated Conditions with Individualized Treatment Approaches:A Comprehensive Review

Introduction: Biomarkers play a pivotal role in the prognosis, risk stratification, and management of cardiovascular diseases (CVDs), which remain the foremost cause of morbidity and mortality globally. Methods: A comprehensive review explores the various types of biomarkers utilized in the treatment of different CVD conditions, presenting the information clearly and concisely. Additionally, this overview summarizes recent clinical trial findings and advances in biomarker research. Results: Recent advancements in biomarker research have identified a range of circulating biomarkers, including high-sensitivity C-reactive protein (hsCRP), cardiac troponins (cTn) and various microRNAs, that enhance the predictive accuracy for cardiovascular events. These biomarkers are derived from diverse pathophysiological processes such as inflammation, endothelial dysfunction and MI. Discussion: As versatile tools, biomarkers serve as prognostic indicators, diagnostic markers, intermediate and surrogate endpoints, and safety monitors, making them essential in personalized medicine. In this context, biomarker-guided cardiovascular therapies represent an advanced approach, allowing clinicians to customize treatment choices and track therapeutic effectiveness in real time. In addition, nanobiotechnology-based systems are also pivotal in personalized medicine, offering targeted therapeutic delivery for CVDs, particularly in addressing heart cell death. Moreover, artificial intelligence, which is emerging as a useful tool in biomarker-guided, personalized cardiovascular treatment, is improving patient care and aiding cardiologists. Conclusion: Recent strides in biomarker research suggest that personalized medicine guided by circulating biomarkers could revolutionize CVD management by enhancing risk prediction and tailoring treatments to each patient. Future research should focus on refining these biomarkers and addressing current limitations to optimise their clinical utility in improving cardiovascular health outcomes.